Close Menu

NEW YORK – Ambry Genetics and Caris Life Sciences today announced a partnership on cancer genetic testing in the US.

Under the terms of the agreement, Caris will offer Ambry's 67-gene CancerNext-Expanded gene panel to evaluate hereditary risk of cancer alongside its Caris Molecular Intelligence tumor profiling. 

Financial and other terms of the partnership were not disclosed. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.